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Abstract
Objective—17-alpha hydroxyprogesterone caproate (17-OHPC) 250 mg weekly reduces
recurrent spontaneous preterm birth (SPTB) in women with a prior SPTB by 33%. The dose is not
based on pharmacological considerations. A therapeutic concentration has not been determined
hampering any attempt to optimize treatment. This study evaluated the relationship between 17-
OHPC plasma concentrations and the rate of SPTB in women with singleton gestation.
Study Design—A single blood sample was obtained between 25 and 28 weeks gestation from
315 women with a SPTB who participated in a placebo-controlled, prospective, randomized
clinical trial evaluating the benefit of omega-3 supplementation in reducing preterm birth. All
women in the parent study received 17-OHPC and 434 received omega-3 supplementation and
418 received a placebo. Plasma from 315 consenting women was analyzed for 17-OHPC
concentration.
Results—There were no differences between placebo and omega-3 supplemented groups in
demographic variables, outcomes or in mean 17-OHPC concentration. Plasma concentrations of
17-OHPC ranged from 3.7- 56 ng/ml. Women with plasma concentrations of 17-OHPC in the
lowest quartile had a significantly higher risk of spontaneous preterm birth (p= 0.03) and delivered
at significantly earlier gestational ages (p = 0.002) than did women in the 2nd to 4th quartiles. The
lowest preterm birth rates were seen when median 17-OHPC concentrations exceeded 6.4 ng/ml.
Conclusions—Low plasma 17-OHPC concentration is associated with an increased risk of
SPTB. This finding validates efficacy of this treatment but suggests that additional studies are
needed to determine the optimal dosage.
Keywords
dose response; 17 hydroxyprogesterone caproate concentration-response; pharmacodynamics
Introduction
17-hydroxyprogesterone caproate (17-OHPC) reduces recurrent spontaneous preterm birth
(SPTB) in women with a singleton gestation and a prior SPTB1. The American College of
Obstetricians and Gynecologists endorses the use of 17-OHPC in women with a prior SPTB
but notes that more research is required as to the optimal formulation and dosage2.
Fundamental to any pharmaceutical intervention is the establishment of an appropriate dose
that has been determined in dose ranging studies that compare efficacy and harms over a
range of doses3,4. There are no data providing guidance on the optimal dose of 17-OHPC.
The dose utilized in the Maternal-Fetal Medicine Network (MFMU) trial reported by Meis
et al1 was 250 mg weekly given as an intramuscular (IM) injection. This dose was chosen
based on the dosage used in previous studies and a meta-analysis5-8. In the MFMU trial a
33% reduction in recurrent SPTB rates was seen in women receiving weekly injections of
250 mg 17-OHPC compared with those receiving placebo. Whether a higher dose would
have provided greater benefit or even harm is not known.
The outcome of interest for 17-OHPC against which various doses can be evaluated, is
SPTB but dose ranging studies are difficult to complete given the large sample size that
would be needed. An alternative approach is to relate plasma drug concentration to the
frequency of preterm birth to assess if a concentration – outcome relationship exists9-12. The
purpose of this study was to evaluate the relationship between 17-OHPC concentration and
gestational length in women with singleton gestation.
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This study utilized blood samples obtained from women who participated in the Omega-3
Maternal-Fetal Medicine Units Network (MFMU) trial that evaluated whether omega-3
supplementation reduced the rate of recurrent SPTB in women with a singleton gestation
and a prior SPTB. All women received weekly intramuscular (IM) injections of 250 mg 17-
OHPC starting between 16 0/7 −21 6/7 weeks and continuing until delivery or 36 6/7 weeks.
In addition, subjects were randomly assigned to receive a daily supplement containing 1,200
mg of eicosapentaenoic acid (EPA, 20:5n-3) and 800 mg of docosahexaenoic acid (DHA,
22:6n-3), for a total of 2,000 mg of omega-3 long-chain polyunsaturated fatty acids, divided
into four capsules, or they received matching placebo capsules that contained only a minute
amount of inert mineral oil. A blood sample was obtained between 25-28 weeks gestation
just prior to the next scheduled dose of 17-OHPC and analyzed for the plasma concentration
of 17-OHPC using high performance liquid chromatography- mass spectrometry with a limit
of detection of 1 ng/ml13.
Statistical Analysis
The analysis was restricted to women who completed all their scheduled 17-OHPC
injections. Demographic data were compared between the two treatment groups using chi-
square or the Wilcoxon test as appropriate. A logistic regression with an interaction term
was conducted to determine whether there was an interaction between 17-OHPC
concentration and treatment group with respect to the outcome of preterm birth. Survival
curve analysis with indicated and term births censored was performed to compare length of
gestation between women in the first and other three quartiles. A proportional hazards model
was performed with adjustment for gestational age at study entrance, gestational age at
blood sampling, race, ethnicity and body mass index (BMI) to assess the relationship
between 17-OHPC plasma concentrations and gestational age at delivery. A nominal p-value
<0.05 was considered significant with no adjustments for multiple comparisons. All tests
were two-sided.
Results
Among the 852 women enrolled in the trial, 434 were randomized to receive omega-3
supplements and 418 were randomized to receive placebo. Blood samples were available on
512 subjects: 261 women in the omega-3 group and 251 in the placebo group. Among these
women 162 in the omega-3 group and 153 in the placebo group received all of their
scheduled 17-OHPC injections throughout the study and form the study population for this
analysis. These women had received a median of 9 injections at the time of blood sampling
which occurred at a mean gestational age of 27 weeks.
Table 1 summarizes the demographic and clinical characteristics of the study cohort
stratified by omega-3 group assignment. There were no differences between the two groups
in any of the parameters listed in the table. Mean plasma 17-OHPC concentrations were
similar in the two treatment groups as were BMI and progesterone concentrations. A wide
variation in plasma 17-OHPC concentrations was seen in both treatment groups with
concentrations ranging from 3.7 ng/ml to 56 ng/ml in the entire cohort.
Because there were no differences in plasma 17-OHPC or progesterone concentrations and
no interaction effect between 17-OHPC concentration and treatment group (p=0.52), we
combined the two treatment groups for further analyses. Due to the large variation in 17-
OHPC concentrations, we stratified the concentration data by quartiles (Table 2). The SPTB
rate was significantly (p< 0.03) greater among women in the first quartile compared with
those in the other quartiles. Also, as demonstrated in the Kaplan-Meier curve of Figure 1,
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women in the first quartile of 17-OHPC concentration delivered significantly earlier than
those in other quartiles (p=0.002). In a proportional hazards model, after controlling for the
gestational age when the subject started treatment with 17-OHPC, the gestational age at
blood sampling, treatment group assignment, BMI, race and ethnicity, those women in the
combined second to fourth quartiles showed a 50% reduction in the hazard of delivering
preterm (hazard ratio = 0.48, 95% confidence limits 0.31-0.75, p=0.001) compared with
those women with plasma 17-OHPC concentrations in the first quartile.
To assess the relationship between concentration of 17-OHPC and SPTB rates, we compared
the median 17-OHPC concentration in each quartile with the SPTB rate for each quartile in
Figure 2. The SPTB rate was highest among women in the first quartile with median plasma
17-OHPC concentrations of 6.4 ng/ml.
Comment
We have demonstrated a significant relationship between the concentration of 17-OHPC and
the rate of recurrent SPTB; rates were lower among women with higher concentrations of
17-OHPC. This observation has several important implications related to 17-OHPC
specifically and progestin supplementation in general. First, the inverse relationship between
17-OHPC concentration and SPTB rates in this cohort of women indicates that 17-OHPC
effectively reduced SPTB rates in some women regardless of omega 3 supplementation.
Efficacy of 17-OHPC in this cohort could otherwise not be assessed since all women
received 17-OHPC. The parent trial was not intended to evaluate the efficacy of 17-OHPC
but rather the efficacy of omega-3 supplementation.
Secondly, the findings in this trial support the conclusions of the MFMU Network study
reported by Meis et al1 that 17-OHPC treatment reduces the rate of preterm birth. Blood
samples were not obtained in that study, preventing any estimate of therapeutic
concentration or any description of a drug concentration- outcome relationship.
Thirdly, in the study reported by Meis et al1, the rate of SPTB before 37 weeks in women
treated with 17-OHPC was reduced by 33%. The findings reported in the current study
suggest that the effectiveness of 17-OHPC in reducing preterm birth rates may be influenced
by the plasma concentration. Whether rates of preterm birth in women with a prior preterm
birth can be improved by administering doses that provide higher concentrations of 17-
OHPC remains to be tested. All women received a dose of 250 mg weekly but plasma
concentrations varied substantially. Similar variation in 17-OHPC concentration has been
reported in women with singleton or twin gestation14,15. This variation is at least in part
attributable to differences in BMI but we have also demonstrated that endogenous
pregnancy-related hormones can affect plasma 17-OHPC concentration16. Additional
variation in plasma 17-OHPC concentration may be seen with certain medications that
compete with the cytochrome P450 enzyme CYP3A4 which is a primary metabolic pathway
for 17-OHPC and several commonly used medications17.
For most pharmaceuticals the proper dose is established by measuring clinical endpoints
over a range of doses. Such studies have not been performed with 17-OHPC. The currently
recommended dose of 17-OHPC of 250 mg weekly was empirically chosen based on
literature that was not informed by pharmacological data defining a proper dose or a
therapeutic concentration5-8. Ideally, the optimal dosage of 17-OHPC should be determined
by dose ranging studies. However, because a very large sample size is required when
preterm birth is the endpoint, we have relied on assessing the relationship between plasma
concentrations and the incidence of preterm birth. This study design is not optimal in that a
single dose was administered and the range of plasma concentrations achieved was narrower
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than what could be expected from a study with a wider drug concentration range.
Specifically, such information could define a therapeutic range as well as a concentration
above which no therapeutic benefit is seen or where harms may be seen. Our data suggest
that clinical benefit may be improved in some women with higher plasma concentrations.
Our data are not informative about benefits or harms related to higher concentrations of 17-
OHPC.
We used median 17-OHPC concentrations from each quartile of 17-OHPC concentrations to
develop the concentration-response relationship, a statistical approach that is not as stringent
as a dose ranging study. Nevertheless, this approach provides information that has
heretofore not been available for singleton gestations. Our results require validation in other
cohorts of women treated with 17-OHPC. We do not believe dosage adjustments of 17-
OHPC should be based on this single secondary analysis.
This and other reports from the MFMU indicate that 17-OHPC supplementation may have
different effects on different populations of at risk women. For example, higher
concentrations of 17-OHPC in twin gestations are associated with a shortened gestational
length, an association opposite to that seen in singleton gestations12. Thus, increasing the
dose of 17-OHPC in women with twin gestation would not be predicted to improve
outcome. Indeed, in a study of women with twins and a short cervix, a dose of 500mg IM
twice weekly led to an increase in risk of preterm birth when compared to women receiving
no 17-OHPC18. On the other hand it is not clear whether higher doses of 17-OHPC would
improve outcomes in women who receive 17-OHPC for the indication of short cervix. In the
only trial of 17-OPHC treatment of low risk asymptomatic women with a short cervix,
Grobman et al reported that 17-OHPC did not reduce preterm birth rates among women with
a singleton gestation and a cervical length less than the 10th percentile (<30 mm)19.
Durnwald et al reported that a dose of 250 mg weekly 17-OHPC did not affect the rate of
cervical change in women with a prior preterm birth20. However, Facchinetti reported a
reduction in the rate of cervical shortening in women with treated preterm labor receiving
341 mg twice weekly 17-OHPC21. The dose used by Facchinetti was 2.5 times the standard
dose used in the United States. Whether the lack of benefit from 17-OHPC in Grobman’s
study is due to an inadequate dose is unknown. Likewise it is not known, if in that cohort of
subjects, a concentration-response relationship exists between 17-OHPC concentration and
preterm birth rates.
Our findings have significance for progesterone supplementation in general. The mechanism
of action of vaginal progesterone or 17-OHPC in reducing preterm birth rates is not known
nor is the target tissue. The demonstration of a 17-OHPC concentration relationship to the
outcome of preterm birth provides support for the concept that progesterone
supplementation can reduce preterm birth rates despite high plasma progesterone
concentrations in pregnancy that exceed the concentration required to half saturate the
progesterone receptor.
In summary, we have demonstrated a relationship between 17-OHPC concentration and the
outcome of spontaneous preterm birth in women with singleton gestation and a prior preterm
birth. Further study is required to fully characterize this relationship. We do not recommend
changing the current dose of 17-OHPC without additional studies to fully characterize the
concentration or dose relationship between 17-OHPC and the rate of recurrent SPTB.
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Condensation: Low 17-OHPC plasma concentration is associated with an increased risk
of spontaneous preterm birth.
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The data reflect the estimated distributions of gestational age at delivery for subjects with
plasma 17-OHPC concentrations in the first quartile vs quartiles 2-4 combined.
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Relationship between median 17-OHPC concentration from each quartile (Q1-Q4) of 17-
OPHC concentrations and the rate of spontaneous preterm birth for each of those quartiles.
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Table 1
Demographic Characteristics of Population
Omega-3 Placebo p value
Cases 162 153
BMI, mean (SD) 26.0 (6.1) 26.1 (6.9) 0.81
Race, N(%) 0.89
 African American 43 (26.5%) 44 (28.8%)
 Hispanic 24 (14.8%) 21 (13.7%)
 Caucasian 95 (58.6%) 88 (57.5%)
GA (weeks) @ sample time, mean (SD) 27.0 (1.4) 26.9 (1.5) 0.25
GA (weeks) @ delivery, mean (SD) 37.4 (2.3) 37.0 (3.0) 0.76
Progesterone (ng/ml), mean (SD) 72.4 (26.9) 70.5 (22.1) 0.63
17-OHPC (ng/ml), mean (SD) 11.3 (5.8) 10.7 (4.0) 0.79
# of injections at time of blood sample,
median (interquartile range)
9 (7-10) 9 (7-10) 0.26
Delivery < 37 0/7 weeks 53 (32.7%) 53 (34.6%) 0.72
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